Imonogas + Espumisan
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Dyspepsia
Conditions
Functional Dyspepsia
Trial Timeline
Feb 1, 2016 → Dec 1, 2016
NCT ID
NCT02660372About Imonogas + Espumisan
Imonogas + Espumisan is a phase 3 stage product being developed by Johnson & Johnson for Functional Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT02660372. Target conditions include Functional Dyspepsia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02660372 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Dyspepsia